Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study

INTRODUCTION: The efficacy and safety of recombinant factor VIII Fc fusion protein (rFVIIIFc) as an extended half‐life treatment for severe haemophilia A were demonstrated in the Phase 3 A‐LONG and Kids A‐LONG studies. Eligible subjects who completed A‐LONG and Kids A‐LONG could enrol in ASPIRE (NCT...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Haemophilia
Glavni autori: Nolan, Beatrice, Mahlangu, Johnny, Pabinger, Ingrid, Young, Guy, Konkle, Barbara A., Barnes, Chris, Nogami, Keiji, Santagostino, Elena, Pasi, K. John, Khoo, Liane, Winding, Bent, Yuan, Huixing, Fruebis, Joachim, Rudin, Dan, Oldenburg, Johannes
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2020
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7384031/
https://ncbi.nlm.nih.gov/pubmed/32227570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/hae.13953
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items